You are not serious are you? We are not talking about job descrimination or such things here, the phisiological difference, levels of different hormones, level of tollerance etc, etc is huge, off course it is possible to work with men and not women. I think if they have enough data on safety from phaseII trials, the commiti may forgive them for size of phaseIII trial, which is not absurdly small. By the way, they will probably halt trading tomorrow, and not open until after the decision. On cancer drugs, specially on refractory indications, anything is possible, they figuire better give doctors one more tool, what have they got to lose?